ANDA 40612, held by Fresenius Kabi USA. Methylprednisolone Sodium Succinate.
As of Nov 21, 2026, ANDA 40612 (Methylprednisolone Sodium Succinate), held by Fresenius Kabi USA, was first approved by FDA on Aug 12, 2004, with 6 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection sterile powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 12, 2004 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Methylprednisolone Sodium SuccinateEQ 1GM BASE/VIAL · injectable;injection | Methylprednisolone Sodium Succinate | Rx |
| Jul 3, 2025 | Supplement 15Labeling · Standard review | Approved | None posted |
| Jul 3, 2025 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 7, 2023 | Supplement 12Labeling · Standard review | Approved | None posted |
| Aug 6, 2020 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 13, 2015 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 13, 2015 | Supplement 6Labeling · Standard review | Approved | None posted |
| Aug 12, 2004 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters